CSF Aβ42, Tau and phosphorylated Tau, APOE ε4 allele and MCI type in progressive MCI

Neurobiology of Aging

Volumn 28, Issue 4, 2007, Pages 507-514

  Herukka, Sanna Kaisa ^a   Helisalmi, Seppo ^a   Hallikainen, Merja ^a   Tervo, Susanna ^a   Soininen, Hilkka ^a,b   Pirttilä, Tuula ^a,b  

^a Clinical Research Center   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

A 42; Alzheimer's disease; Apolipoprotein E; Mild cognitive impairment; Phosphorylated Tau; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; AMNESIA; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANALYSIS OF VARIANCE; CEREBROSPINAL FLUID; COMPARATIVE STUDY; GENETICS; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PREDICTION AND FORECASTING; SURVIVAL;

AGED; ALLELES; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; COGNITION DISORDERS; DEMENTIA; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TAU PROTEINS;

EID: 33847204043     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.02.001     Document Type: Article

References (58)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), APA, Washington
2. Amieva H., Letenneur L., Dartigues J.F., Rouch-Leroyer I., Sourgen C., D'Alchee-Biree F., et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 18 (2004) 87-93
3. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Cerebrospinal fluid levels of total-Tau, phospho-Tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 179 Suppl (2003) 47-51
4. Bennett D.A., Schneider J.A., Bienias J.L., Evans D.A., and Wilson R.S. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64 (2005) 834-841
5. Borkowski J.G., Benton A.L., and Spreen O. Word fluency and brain damage. Neuropsychologia 5 (1967) 135-140
6. Bozoki A., Giordani B., Heidebrink J.L., Berent S., and Foster N.L. Mild cognitive impairments predict dementia in non-demented elderly patients with memory loss. Arch Neurol 58 (2001) 411-416
7. Butters N., Granholm E., Salmon D.P., Grant I., and Wolfe J. Episodic and semantic memory: a comparison of amnesic and demented patients. J Clin Exp Neuropsychol 9 (1987) 479-497
8. Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., et al. Cerebrospinal fluid Tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 60 (2003) 1696-1702
9. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
10. Davis D.G., Schmitt F.A., Wekstein D.R., and Markesbery W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58 (1999) 376-388
11. DeCarli C., Mungas D., Harvey D., Reed B., Weiner M., Chui H., et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 63 (2004) 220-227
12. Elias M.F., Beiser A., Wolf P.A., Au R., White R.F., and D'Agostino R.B. The preclinical phase of Alzheimer disease: a 22-year prospective study of the framingham cohort. Arch Neurol 57 (2000) 808-813
13. Engelborghs S., Dermaut B., Goeman J., Saerens J., Marien P., Pickut B.A., et al. Prospective belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatr 74 (2003) 1148-1151
14. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278 (1997) 1349-1356
15. Flicker C., Ferris S.H., and Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 41 (1991) 1006-1009
16. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
17. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., et al. High cerebrospinal fluid Tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998) 937-945
18. Ganguli M., Dodge H.H., Shen C., and DeKosky S.T. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 63 (2004) 115-121
19. Grundman M., Petersen R.C., Ferris S.H., Thomas R.G., Aisen P.S., Bennett D.A., et al., Alzheimer's Disease Cooperative Study. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61 (2004) 59-66
20. Hampel H., Teipel S.J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., et al. Value of CSF beta-amyloid(1-42) and Tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatr 9 7 (2004) 705-710
21. Herukka S.K., Hallikainen M., Soininen H., and Pirttila T. CSF Abeta42 and Tau or phosphorylated Tau and prediction of progressive mild cognitive impairment. Neurology 64 (2005) 1294-1297
22. Hsiung G.Y., Sadovnick A.D., and Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the canadian study of health and aging. CMAJ 171 (2004) 863-867
23. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and Tau levels in CSF. Neurology 52 (1999) 1555-1562
24. Jack Jr. C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52 (1999) 1397-1403
25. Kaplan E.F., Goodglass H., and Weintraub S. The boston naming test (1991), Kaplan and Goodglass, Boston
26. Kawas C.H., Corrada M.M., Brookmeyer R., Morrison A., Resnick S.M., Zonderman A.B., et al. Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 60 (2003) 1089-1093
27. Killiany R.J., Hyman B.T., Gomez-Isla T., Moss M.B., Kikinis R., Jolesz F., et al. MRI measures of entorhinal cortex versus hippocampus in preclinical AD. Neurology 58 (2002) 1188-1196
28. Lehtimaki T., Moilanen T., Viikari J., Akerblom H.K., Ehnholm C., Ronnemaa T., et al. Apolipoprotein E phenotypes in finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res 31 (1990) 487-495
29. Luis C.A., Barker W.W., Loewenstein D.A., Crum T.A., Rogaeva E., Kawarai T., et al. Conversion to dementia among two groups with cognitive impairment. A preliminary report. Dement Geriatr Cogn Disord 18 (2004) 307-313
30. Maruyama M., Matsui T., Tanji H., Nemoto M., Tomita N., Ootsuki M., et al. Cerebrospinal fluid Tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol 61 (2004) 716-720
31. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34 (1984) 939-944
32. Meyer J., Xu G., Thornby J., Chowdhury M., and Quach M. Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging. J Neurol Sci 201 (2002) 19-25
33. Morris J.C., and Price A.L. Pathologic correlates of non-demented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 17 (2001) 101-118
34. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58 (2001) 397-405
35. Morris J.C. The clinical dementia rating (CDR): current version and scoring rules. Neurology 43 (1993) 2412-2414
36. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39 (1989) 1159-1165
37. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. neuropathology group of the medical research council cognitive function and ageing study (MRC CFAS). Lancet 357 (2001) 169-175
38. Pennanen C., Kivipelto M., Tuomainen S., Hartikainen P., Hanninen T., Laakso M.P., et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 25 (2004) 303-310
39. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005)
40. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., et al. Current concepts in mild cognitive impairment. Arch Neurol 58 (2001) 1985-1992
41. Petersen R.C., Smith G.E., Ivnik R.J., Tangalos E.G., Schaid D.J., Thibodeau S.N., et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273 (1995) 1274-1278
42. Prince J.A., Zetterberg H., Andreasen N., Marcusson J., and Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62 (2004) 2116-2118
43. Rasquin S.M., Lodder J., Visser P.J., Lousberg R., and Verhey F.R. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Dement Geriatr Cogn Disord 19 (2005) 113-119
44. Reitan R.M. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8 (1958) 271-276
45. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., and Kurz A. Cerebrospinal fluid Tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59 (2002) 1729-1734
46. Royall D.R., Palmer R., Chiodo L.K., and Polk M.J. Executive control mediates memory's association with change in instrumental activities of daily living: the freedom house study. J Am Geriatr Soc 53 (2005) 11-17
47. Royall D.R., Chiodo L.K., and Polk M.J. Misclassification is likely in the assessment of mild cognitive impairment. Neuroepidemiology 23 (2004) 185-191
48. Russel E.W. A multiple scoring method for the assessment of complex memory functions. J Cons Clin Psychol 43 (1975) 800-809
49. Saxton J., Lopez O.L., Ratcliff G., Dulberg C., Fried L.P., Carlson M.C., et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5-8 years prior to onset. Neurology 63 (2004) 2341-2347
50. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81 (2001) 741-766
51. Skoog I., Davidsson P., Aevarsson O., Vanderstichele H., Vanmechelen E., and Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 15 (2003) 169-176
52. Solfrizzi V., Panza F., Colacicco A.M., D'Introno A., Capurso C., Torres F., et al., Italian Longitudinal Study on Aging Working Group. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 63 (2004) 1882-1891
53. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90 (1993) 1977-1981
54. Strozyk D., Blennow K., White L.R., and Launer L.J. CSF abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (2003) 652-656
55. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., et al. Cerebrospinal fluid beta-amyloid1-42 and Tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatr 56 (2004) 670-676
56. Tsukamoto K., Watanabe T., Matsushima T., Kinoshita M., Kato H., Hashimoto Y., et al. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med 121 (1993) 598-602
57. Wechsler D. Wechsler memory scale, revised manual (1987), Psychological Corporation, San Antonio
58. Wechsler D. Wechsler adult intelligence scale, revised (1981), Psychological Corporation, Cleveland